JP2024536126A - 肝体積を減少させるためのレスメチロム - Google Patents
肝体積を減少させるためのレスメチロム Download PDFInfo
- Publication number
- JP2024536126A JP2024536126A JP2024519112A JP2024519112A JP2024536126A JP 2024536126 A JP2024536126 A JP 2024536126A JP 2024519112 A JP2024519112 A JP 2024519112A JP 2024519112 A JP2024519112 A JP 2024519112A JP 2024536126 A JP2024536126 A JP 2024536126A
- Authority
- JP
- Japan
- Prior art keywords
- resmetirom
- subject
- prodrug
- less
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248634P | 2021-09-27 | 2021-09-27 | |
| US63/248,634 | 2021-09-27 | ||
| PCT/US2022/044826 WO2023049491A1 (en) | 2021-09-27 | 2022-09-27 | Resmetirom for reducing liver volume |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536126A true JP2024536126A (ja) | 2024-10-04 |
| JP2024536126A5 JP2024536126A5 (enExample) | 2026-06-25 |
Family
ID=83900064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519112A Pending JP2024536126A (ja) | 2021-09-27 | 2022-09-27 | 肝体積を減少させるためのレスメチロム |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20240408102A1 (enExample) |
| EP (2) | EP4578499A3 (enExample) |
| JP (1) | JP2024536126A (enExample) |
| KR (1) | KR20240073926A (enExample) |
| CN (1) | CN118251221A (enExample) |
| AR (1) | AR127165A1 (enExample) |
| AU (1) | AU2022348966A1 (enExample) |
| CA (1) | CA3233319A1 (enExample) |
| CL (1) | CL2024000886A1 (enExample) |
| IL (1) | IL311670A (enExample) |
| MX (1) | MX2024003967A (enExample) |
| TW (1) | TW202337470A (enExample) |
| WO (1) | WO2023049491A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024251233A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都微芯药业有限公司 | PPAR全激动剂联合THR-β激动剂在抗代谢相关疾病中的用途 |
| JP2026521649A (ja) * | 2023-06-22 | 2026-06-30 | マドリガル ファーマシューティカルズ インコーポレイテッド | ＴＨＲ－βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用 |
| KR20260000642A (ko) * | 2024-06-25 | 2026-01-05 | 연세대학교 산학협력단 | Usp10 억제제를 유효성분으로 포함하는, 간섬유증 또는 간섬유증 관련 질환의 예방 또는 치료용 조성물 |
| WO2026107045A1 (en) * | 2024-11-12 | 2026-05-21 | Madrigal Pharmaceuticals, Inc. | Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE480524T1 (de) | 2005-07-21 | 2010-09-15 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| ES2795450T3 (es) | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| MX394463B (es) | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| TW202615431A (zh) | 2018-07-02 | 2026-04-16 | 美商瑪德瑞高製藥公司 | ２－（３，５－二氯－４－（（５－異丙基－６－側氧基－１，６－二氫噠嗪－３－基）氧）苯基）－３，５－二側氧基－２，３，４，５－四氫－１，２，４－三嗪－６－腈之固體型式 |
| CA3111025C (en) * | 2018-09-06 | 2023-10-31 | Galmed Research And Development Ltd | Combination therapy for the treatment of liver disease |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| CA3195960A1 (en) | 2020-10-23 | 2022-04-28 | Madrigal Pharmaceuticals, Inc. | Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues |
-
2022
- 2022-09-27 TW TW111136510A patent/TW202337470A/zh unknown
- 2022-09-27 IL IL311670A patent/IL311670A/en unknown
- 2022-09-27 EP EP24212126.7A patent/EP4578499A3/en active Pending
- 2022-09-27 MX MX2024003967A patent/MX2024003967A/es unknown
- 2022-09-27 US US18/695,572 patent/US20240408102A1/en active Pending
- 2022-09-27 CN CN202280075697.1A patent/CN118251221A/zh active Pending
- 2022-09-27 EP EP22793025.2A patent/EP4408428A1/en not_active Withdrawn
- 2022-09-27 JP JP2024519112A patent/JP2024536126A/ja active Pending
- 2022-09-27 CA CA3233319A patent/CA3233319A1/en active Pending
- 2022-09-27 AR ARP220102600A patent/AR127165A1/es unknown
- 2022-09-27 KR KR1020247013928A patent/KR20240073926A/ko active Pending
- 2022-09-27 WO PCT/US2022/044826 patent/WO2023049491A1/en not_active Ceased
- 2022-09-27 AU AU2022348966A patent/AU2022348966A1/en active Pending
-
2024
- 2024-03-26 CL CL2024000886A patent/CL2024000886A1/es unknown
-
2025
- 2025-11-12 US US19/386,839 patent/US12661361B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20260069598A1 (en) | 2026-03-12 |
| IL311670A (en) | 2024-05-01 |
| MX2024003967A (es) | 2024-06-03 |
| US12661361B2 (en) | 2026-06-23 |
| AU2022348966A1 (en) | 2024-04-11 |
| US20240408102A1 (en) | 2024-12-12 |
| CN118251221A (zh) | 2024-06-25 |
| EP4408428A1 (en) | 2024-08-07 |
| CL2024000886A1 (es) | 2024-08-30 |
| KR20240073926A (ko) | 2024-05-27 |
| WO2023049491A1 (en) | 2023-03-30 |
| AR127165A1 (es) | 2023-12-27 |
| CA3233319A1 (en) | 2023-03-30 |
| EP4578499A2 (en) | 2025-07-02 |
| TW202337470A (zh) | 2023-10-01 |
| EP4578499A3 (en) | 2025-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11400072B2 (en) | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy | |
| US20260069598A1 (en) | Resmetirom for reducing liver volume | |
| CA3018132C (en) | Use of elafibranor in the treatment of a cholestatic disease | |
| JP6941109B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| JP6986022B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| CN105764498A (zh) | 纯合家族型高胆固醇血症的治疗 | |
| US11331292B2 (en) | Methods of treatment of cholestatic diseases | |
| CN101646686A (zh) | 铁过剩症的预防或治疗剂 | |
| US20240423992A1 (en) | Biomarkers for treating liver disorders with thr-b agonists and related uses | |
| HK40128789A (en) | Resmetirom for reducing liver volume | |
| JP2021534208A (ja) | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 | |
| TW202245775A (zh) | 用於治療肝病症或脂質病症之瑞舒伐他汀（Ｒｏｓｕｖａｓｔａｔｉｎ）和瑞司美替隆（Ｒｅｓｍｅｔｉｒｏｍ）的治療組合 | |
| JP2023544220A (ja) | 肝疾患を治療するための併用療法 | |
| RU2850978C1 (ru) | Применение агониста рецептора сфингозин-1-фосфата | |
| HK40096516A (en) | Methods of treatment of cholestatic diseases | |
| WO2025224044A1 (en) | Methods of treatment of primary biliary cholangitis | |
| TW202539665A (zh) | Fgfr4抑制劑與ppar促效劑之組合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250929 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250929 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260617 |